Cost Plus Drugs Company Overview & Business Model

What Is Cost Plus Drugs and How Does the Business Model Work?

Cost Plus Drugs operates on a radically simplified pricing formula: it publishes the exact price it pays manufacturers, then adds 15% gross margin, a flat $3 pharmacist fee, and $5 for shipping. Every cost component is printed on the product page. This level of price transparency is uncommon in U.S. Pharmacy retail, where the spread between manufacturer invoice and patient copay is typically hidden inside contracts between pharmacy benefit managers (PBMs), insurers, and pharmacies.

The Role of PBMs in Traditional Drug Pricing

To understand why Cost Plus Drugs exists, it helps to understand what it bypasses. PBMs, including Express Scripts, CVS Caremark, and OptumRx, negotiate rebates from drug manufacturers and set reimbursement rates to pharmacies. Research published in the Journal of the American Medical Association found that PBM spread pricing on generic drugs in Ohio Medicaid averaged $1.37 per prescription above the actual ingredient cost, with a total spread exceeding $224 million in a single year [1]. A separate analysis in Health Affairs documented that PBM "clawbacks" sometimes cause patients to overpay even when their insurer's contracted price exceeds the cash price at the same pharmacy [2].

Cost Plus Drugs removes this layer entirely. The company manufactures some drugs through its own 503B-registered outsourcing facility and sources others directly from generic manufacturers, then ships through its mail-order pharmacy licensed in Texas.

The 15% Markup in Context

Retail pharmacy gross margins on generics vary widely. A 2021 analysis in JAMA Internal Medicine found that median retail pharmacy gross margins on generic drugs ranged from 33% to over 300% depending on the molecule, insurer contract, and dispensing channel [3]. Cost Plus Drugs' fixed 15% cap is therefore substantially below typical retail. The company has publicly stated it targets net margins near zero on the pharmacy operation, treating drug savings as the product itself.

Manufacturing Arm and Vertical Integration

In 2023, Cost Plus Drugs opened a 22,000-square-foot manufacturing facility in Dallas registered with the FDA as a 503B outsourcing facility [4]. The FDA's 503B framework, established under the Drug Quality and Security Act of 2013, allows compounding pharmacies to produce medications in bulk for office use and to supply healthcare facilities without individual patient-specific prescriptions [5]. The facility currently produces injectable medications including certain chemotherapy agents and hospital-use drugs, allowing Cost Plus to further reduce cost by eliminating a distribution intermediary.

Is Cost Plus Drugs Legitimate?

Cost Plus Drugs is a legitimately licensed pharmacy. It holds an active .pharmacy domain credential issued by the National Association of Boards of Pharmacy (NABP), which requires applicants to demonstrate state licensure, compliance with federal law, and a valid prescription requirement for all Rx medications [6]. The NABP's .pharmacy program was established specifically to help patients distinguish safe online pharmacies from the estimated 95% of internet pharmacy websites that operate illegally according to NABP's own surveys [7].

State Licensure and FDA Oversight

The dispensing pharmacy operates under a Texas state pharmacy license and is subject to routine inspection. The manufacturing facility in Dallas is registered with the FDA and subject to current Good Manufacturing Practice (cGMP) regulations under 21 CFR Parts 210 and 211 [8]. These are the same standards that apply to commercial drug manufacturers.

Prescription Requirements

Every controlled substance is excluded from the Cost Plus catalog. All prescription medications require a valid prescription from a licensed U.S. Prescriber. The company does not provide telemedicine services itself, though patients may use any telehealth platform or their own physician to generate a prescription and then route it to Cost Plus Drugs for fulfillment.

What the BBB and Consumer Reviews Say

The company holds an A rating with the Better Business Bureau as of mid-2025. Patient reviews across independent platforms consistently cite fast shipping (typically 3 to 5 business days) and accurate pricing as strengths. Common complaints involve occasional stock-outs of high-demand generics and the absence of insurance billing. These are structural features of the business model rather than compliance failures.

What Drugs Does Cost Plus Drugs Carry?

The catalog covers approximately 2,500 generic and off-patent medications spanning most major therapeutic categories. The following drug classes are well-represented.

Metabolic and Endocrine Medications

Generic metformin 500 mg (60 tablets) is listed at $3.20. Generic levothyroxine 50 mcg (90 tablets) is available at prices that undercut most retail cash prices by 60 to 80%. Semaglutide is not currently in the Cost Plus catalog because it remains under Novo Nordisk's brand patent (Ozempic, Wegovy); however, tirzepatide is similarly absent for the same reason. Patients seeking GLP-1 agonists for weight management will need to look elsewhere, including FDA-approved brand dispensing through specialty pharmacy or, where legally compounded versions exist, through a licensed 503B compounder [9].

Oncology and Specialty Generics

This is where Cost Plus Drugs delivers the most dramatic savings. Generic imatinib (the generic equivalent of Gleevec, used in chronic myeloid leukemia) is listed at $17.10 for 30 tablets of 100 mg. The FDA approved the first generic imatinib in 2016 [10], yet retail cash prices for brand Gleevec remained above $9,000 per month at major chains for years afterward, a pricing anomaly documented in a 2019 JAMA Oncology analysis [11].

Cardiovascular and Psychiatric Medications

Generic atorvastatin, lisinopril, amlodipine, sertraline, bupropion, and escitalopram are all listed at prices ranging from $3 to $18 for a 30- to 90-day supply. The American Heart Association's 2023 guideline update on statin therapy noted that cost barriers contribute to non-adherence, which independently increases cardiovascular event rates [12]. Lowering out-of-pocket cost for statins from $30, $60 per month (common retail cash price) to under $10 may have real clinical impact on adherence.

What Is Not Available

Controlled substances (Schedule II, V) are absent. Most brand-name medications still under patent are absent. Biologics and biosimilars, including adalimumab biosimilars, are not listed despite FDA approval of multiple interchangeable adalimumab products since 2023 [13]. Specialty pharmacy medications requiring cold-chain handling or REMS programs are largely excluded.

Cost Plus Drugs vs. Alternatives

Several competitors occupy adjacent market positions. Choosing among them depends on drug class, insurance status, and prescribing channel.

Cost Plus Drugs vs. GoodRx

GoodRx is a discount card and price-comparison platform, not a pharmacy. It negotiates discounted cash prices with retail pharmacy chains and passes a portion of the discount to patients via coupon codes. A 2023 JAMA Network Open study found that GoodRx prices were lower than Medicare Part D patient cost-sharing for 23% of sampled medications [14]. Cost Plus Drugs' fixed-markup model often, though not always, beats GoodRx prices on the same molecule. The key difference is that GoodRx works at any participating retail pharmacy and offers broader drug coverage including some brand-name drugs, while Cost Plus requires mail-order and covers only its catalog.

Cost Plus Drugs vs. Amazon Pharmacy

Amazon Pharmacy offers both insurance billing and a cash-pay subscription called RxPass ($5/month, covering roughly 50 common generics for Prime members). For patients who need only the most common primary-care generics and already have Prime, RxPass may be cheaper in aggregate. Amazon Pharmacy also accepts insurance, which Cost Plus does not, making it more versatile for patients with good prescription drug coverage.

Cost Plus Drugs vs. Mark Cuban's Broader Drug-Pricing Mission

The table below summarizes a decision framework for selecting among cash-pay pharmacy options based on drug type and patient situation.

| Patient situation | Recommended channel | |---|---| | Common generic (metformin, lisinopril, SSRI) | Cost Plus Drugs or Amazon RxPass | | Brand-name drug with good insurance | Traditional pharmacy, use insurance | | GLP-1 agonist (semaglutide, tirzepatide) | Specialty pharmacy or licensed telehealth with 503B compound | | Rare generic with high retail markup | Cost Plus Drugs first, then GoodRx as backup | | Controlled substance | Traditional retail pharmacy only | | Rural patient, limited retail access | Cost Plus Drugs mail-order or Amazon Pharmacy |

Cost Plus Drugs vs. Traditional Retail Pharmacy

Traditional retail pharmacy offers same-day dispensing, pharmacist counseling in person, and insurance billing. Cost Plus Drugs offers none of these. For patients managing chronic conditions on stable generic regimens, the 3 to 5 day mail order delay is unlikely to be clinically meaningful. For acute infections or medications required immediately, retail pharmacy remains the practical choice.

Drug Pricing Transparency and Policy Context

Cost Plus Drugs entered the market during a period of intense federal focus on drug pricing. The Inflation Reduction Act of 2022 (IRA) granted Medicare the authority to negotiate prices directly with manufacturers for a defined set of high-expenditure drugs, with the first 10 drugs subject to negotiation announced by CMS in August 2023 [15]. The IRA negotiations apply only to Medicare Part D coverage and do not directly affect retail or cash-pay pricing for commercially insured or uninsured patients.

PBM Reform Legislation

The FTC released a report in July 2024 concluding that the six largest PBMs used their market position to raise drug costs for patients and independent pharmacies while steering prescriptions toward their own affiliated pharmacies [16]. Congressional hearings in 2023 and 2024 featured testimony from independent pharmacists and patient advocates citing the same spread-pricing dynamics that Cost Plus Drugs was designed to circumvent. Legislation targeting PBM transparency remains active in Congress as of mid-2025.

Drug Adherence and Out-of-Pocket Cost

The clinical stakes of drug affordability are well-documented. A systematic review in Annals of Internal Medicine covering 37 studies found that a 10% increase in patient cost-sharing was associated with a 2 to 6% reduction in medication adherence [17]. For cardiovascular medications and diabetes treatments, non-adherence directly increases hospitalization rates and mortality. The American Diabetes Association's 2024 Standards of Medical Care in Diabetes explicitly state: "Insulin cost and access are significant barriers to insulin use; clinicians should factor cost into treatment decisions and consider cost-effective alternatives when possible" [18]. Generic insulin analogs and metformin listed at Cost Plus prices fall well within a cost-effective range by any conventional threshold.

How Much Does Cost Plus Drugs Actually Cost?

Pricing is available in full on the Cost Plus Drugs website. A few representative examples illustrate the range.

Sample Price Comparisons

• Generic metformin 500 mg, 60 tablets: $3.20 at Cost Plus vs. Approximately $14, $25 retail cash
• Generic atorvastatin 20 mg, 90 tablets: $6.60 at Cost Plus vs. Approximately $30, $75 retail cash
• Generic imatinib 100 mg, 30 tablets: $17.10 at Cost Plus vs. Thousands of dollars retail for brand Gleevec
• Generic sertraline 100 mg, 30 tablets: $4.80 at Cost Plus vs. Approximately $15, $40 retail cash
• Generic tamoxifen 20 mg, 30 tablets: $6.90 at Cost Plus vs. Approximately $30, $80 retail cash

All prices include the $3 pharmacist fee and are before the flat $5 shipping charge applied per order (not per medication). An order containing five separate generic medications would incur one $5 shipping fee, making multi-medication orders especially economical.

HSA and FSA Eligibility

Cost Plus Drugs accepts Health Savings Account (HSA) and Flexible Spending Account (FSA) debit cards for prescription medications. Over-the-counter items, if any are added to the catalog, would require an FSA plan that covers OTC purchases under IRS rules [19].

No Insurance Billing

The company does not submit claims to insurance or Medicare Part D. Patients with generous prescription drug coverage may find that their copays under insurance are lower than the Cost Plus cash price for common generics, particularly if their plan uses a tiered formulary with $0 or $5 generic copays. Before switching to Cost Plus, patients should compare their current copay to the Cost Plus price for each specific medication.

Critical Assessment: Strengths and Limitations

Any honest evaluation of Cost Plus Drugs must weigh what it does well against what it does not address.

Genuine Strengths

Price transparency is real and verifiable. The markup formula is published and prices match the formula. Savings on off-patent oncology drugs, older cardiovascular generics, and psychiatric generics are substantial and independently verified. The FDA-registered manufacturing facility adds a layer of quality assurance beyond what many online pharmacies offer. The NABP .pharmacy credential confirms basic compliance with safety standards.

Real Limitations

The catalog of 2,500 drugs, while growing, excludes the majority of U.S. Prescription volume by brand-name sales. Patients on patent-protected drugs, biologics, or specialty medications will find little or nothing at Cost Plus. The cash-only model benefits the uninsured and underinsured most directly; patients with comprehensive drug coverage may see no net savings. Mail-order logistics mean a 3 to 5 day wait, which is unsuitable for acute prescriptions.

Who Benefits Most

Uninsured and underinsured patients on stable chronic-disease regimens stand to gain the most. A patient managing type 2 diabetes with metformin, a statin, an ACE inhibitor, and an antidepressant could potentially reduce annual out-of-pocket drug costs by several hundred dollars per year. The American College of Endocrinology's position on reducing patient cost burden for chronic metabolic diseases supports identifying lowest-cost equivalent generic options as a standard part of prescribing decisions [20].